Skip to main content
Fig. 1 | Parasites & Vectors

Fig. 1

From: Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

Fig. 1

Schematic of the final pharmacokinetic/pharmacodynamic model. The pharmacokinetic model is on the upper half of the figure and the pharmacodynamic model on the lower half. CCYP2D6: concentration in the CYP2D6-mediated metabolite compartment; CLH1: hepatic clearance out of the system; CLH2: CYP2D6-mediated hepatic clearance; CLm: clearance of the metabolite; CYP2D6: cytochrome P450 D6; EH: hepatic extraction ratio; FG6PDd: factor by which the primaquine-induced elimination of erythrocytes is increased in G6PD-deficient individuals; Hb: hemoglobin; Kin: erythrocyte production; Kerythrocyte elimination: primaquine-induced elimination of erythrocytes; Ktr: first-order rate constant defined as 4/LS where LS is the erythrocyte lifespan in hours; MAT: mean absorption time; PD: pharmacodynamic; PK: pharmacokinetic; Slope: concentration-slope effect of primaquine-induced elimination of erythrocytes; VL: liver volume; Vm: volume of the metabolite compartment; VPQ: volume of the primaquine compartment

Back to article page